Justin Zelin
Stock Analyst at BTIG
(2.53)
# 2,409
Out of 5,044 analysts
45
Total ratings
31.11%
Success rate
0.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $13.51 | +314.51% | 4 | Oct 27, 2025 | |
| IMAB I-Mab | Reiterates: Buy | $9 | $4.64 | +93.97% | 4 | Oct 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $33.19 | +86.80% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $1.45 | +451.72% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $34.93 | +257.86% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $2.34 | +199.15% | 3 | Sep 22, 2025 | |
| VSTM Verastem | Reiterates: Buy | $20 | $8.85 | +125.99% | 2 | Sep 9, 2025 | |
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.58 | +132.56% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $21.55 | +94.90% | 1 | Dec 13, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $2.13 | +463.38% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.94 | - | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $1.50 | +53,233.33% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $33.75 | +169.63% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.86 | +1,068.77% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.04 | +426.32% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $14.84 | +149.33% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $32.57 | +176.33% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $10.51 | +194.96% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $52.05 | -70.22% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.58 | +532.91% | 3 | Nov 16, 2022 |
Syndax Pharmaceuticals
Oct 27, 2025
Reiterates: Buy
Price Target: $56
Current: $13.51
Upside: +314.51%
I-Mab
Oct 24, 2025
Reiterates: Buy
Price Target: $9
Current: $4.64
Upside: +93.97%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $33.19
Upside: +86.80%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $1.45
Upside: +451.72%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $34.93
Upside: +257.86%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $2.34
Upside: +199.15%
Verastem
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $8.85
Upside: +125.99%
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.58
Upside: +132.56%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $21.55
Upside: +94.90%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $2.13
Upside: +463.38%
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.94
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.50
Upside: +53,233.33%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $33.75
Upside: +169.63%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.86
Upside: +1,068.77%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $3.04
Upside: +426.32%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $14.84
Upside: +149.33%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $32.57
Upside: +176.33%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $10.51
Upside: +194.96%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $52.05
Upside: -70.22%
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.58
Upside: +532.91%